AFT Pharmaceuticals expects sales to hit analyst forecast of $70 mln

Paul McBeth
Thu, 16 Feb 2017

By Paul McBeth Feb. 17 (BusinessDesk) - AFT Pharmaceuticals, which manufactures the Maxigesic painkiller, expects annual sales to meet analysts' forecasts of about $70 million and has adjusted its loan covenant with shareholder Capital Royalty Group.  The Auckland-based drug maker projects annual sales will rise 9.4 percent in the year ending March 31 and has adjusted the revenue covenant on its CRG loan to meet a sales target of $67.5 million, it said in a statement. AFT had set up a US$30 million six-year facility with CRG in 2014, whic...

Not convinced yet?

Subscribe to our Daily News Update free newsletter.

Property
Red Stag engineers deal with Timberlab
Brent Melville | Tue, 09 Aug 2022

Rotorua-based Red Stag sees the engineered timber group as the glue that will fit the missing pieces of the puzzle together.

Full Page FREE
Register: Prospa webinar – how small businesses can do digital transformation better
Staff reporters | Tue, 09 Aug 2022

The third and final webinar will focus on how small businesses can do digital transformation better and it will go live at midday on Monday, 15 Aug.

The Quiz FREE
QuiznessDesk, Tuesday, Aug 09, 2022
The Quizmaster | Tue, 09 Aug 2022

The wettest month on record has passed, so it's time to enjoy your daily quiz while basking in the sunlight. 

Sponsored
A clearer path to the cloud

Step-by-step cloud transition can bring benefits, experts say.

Sponsored
Energy of the future: Why we need innovation

The Tomorrow’s Energy Today conference is looking at ways to develop a clean, affordable and reliable energy future, says Brendan Winitana, chair of the Sustainable Energy Association New Zealand (SEANZ).